An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Trial Profile

An Open-Label, 2-Cohort, Multicenter, Phase 2 Study of E7080 (Lenvatinib) in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2016

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 13 Mar 2015 According to MD Anderson record the status is terminated. According to CT.gov record it is active, no longer recruiting. The profile reflects CT.gov record because MD Anderson displays centre specific status.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top